peptide analogues of GLP-1 have therefore been developed and successfully used clinically for the treatment of T2D and obesity, including exendin-4, liraglutide, and semaglutide, amongst others (1, 2, 5)
The impact of these drugs is undeniable: They are changing everything, across industries, and not always in the ways you think
Every section below revisits the sermorelin vs CJC-1295 vs ipamorelin framework from a different angle mechanism, combination therapy, protocols, and body composition outcomes
This medication is a GLP-1 receptor agonist that helps regulate appetite and calorie intake in those who are overweight or obese
Washington, DC: The National Academies Press, 2014
As demand surges for semaglutide alternatives like compounded GLP-1 medications, telehealth platforms, compounding pharmacies, and personalized medicine are exposing cracks in the FDAs regulatory systemand reshaping the future of pharma